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and 9 strains of African horse sickness 
virus) (5). The RT-qPCR tests con-
fi rmed BTV viremia.
The yak species in its natural 
biotope is usually rarely exposed to 
competent Culicoides vectors. Anti-
bodies against BTV have been found 
in many wild ruminants (6), and our 
results extend the number of ruminant 
species susceptible to BTV. In the 
northern European BT outbreak, le-
sions in cattle and sheep were mainly 
localized to the regions of the muzzle, 
mouth, and eye; clinical signs were 
not always obvious (7,8). As in cattle 
and sheep, clinical signs in yaks were 
observed on the muzzle, in the perio-
cular region, and around and inside 
the mouth. These signs clearly refl ect-
ed viral-induced endothelial damage 
triggering disseminated intravascular 
coagulation and a hemorrhagic diath-
esis commonly described in sheep and 
cattle (2). In our case, lesions depicted 
pronounced microvascular damage. 
According to the severity of the le-
sions and rates of illness and death ob-
served, the yak, like sheep, appears to 
be highly susceptible to BTV.
In the epidemiology of BT in Afri-
can countries, cattle and wild ruminant 
species such as antelopes play a role 
as asymptomatic reservoir hosts of the 
virus (2). Some wild ruminant species 
in captivity could also play this role 
in European countries affected by the 
recent BT outbreak. These cases could 
be of particular concern for all parks 
and zoos that gather numerous wild 
ruminants. Illness, reproductive fail-
ure, and deaths usually reported with 
BT (9) could generate substantial loss-
es on these premises. Moreover, the 
source of BTV-8 in the northern Eu-
ropean outbreak remains unclear, and 
the role of wild ruminant species has 
to be taken into account. In the future, 
European authorities should consider 
vaccination to prevent the spread of 
the disease in European member states 
(10). All premises with wild ruminants 
need to be involved in BT control and 
prophylaxis.
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Murine Typhus, 
Algeria
To the Editor: Rickettsioses, or 
typhoid diseases, are caused by obli-
gate intracellular bacteria of the order 
Rickettsiales. The ubiquitous murine 
typhus is caused by Rickettsia typhi. 
Although cat fl eas and opposums have 
been suggested as vectors in some 
places in the United States, the main 
vector of murine typhus is the rat fl ea 
(Xenopspylla cheopis), which main-
tains R. typhi in rodent reservoirs (1). 
Most persons become infected when 
fl ea feces containing R. typhi con-
taminate broken skin or are inhaled, 
although infections may also result 
from fl ea bites (1). Murine typhus is 
often unrecognized in Africa; how-
ever, from northern Africa, 7 cases in 
Tunisia were documented in 2005 (2).
We conducted a prospective 
studyin Algeria which included all 
patients who had clinical signs lead-
ing to suspicion of rickettsioses (high 
fever, skin rash, headache, myalgia, 
arthralgia, eschar, or reported contact 
with ticks, fl eas, or lice) who visited 
the Oran Teaching Hospital in 2004–
2005 for an infectious diseases con-
sultation. Clinical and epidemiologic 
data as well as acute-phase (day of 
admission) and convalescent-phase 
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(2–4 weeks later) serum samples were 
collected. Serum samples were sent to 
the World Health Organization Col-
laborative Center for Rickettsial Dis-
eases in Marseille, France. They were 
tested by immunofl uoresence assay 
(IFA), by using spotted fever group 
(SFG) rickettsial antigens (R. conorii 
conorii, R. conorii israelensis, R. si-
birica mongolitimonae, R. aeschlim-
manii, R. massiliae, R. helvetica, R. 
slovaca, and R. felis) and R. typhi and 
R. prowazekii as previously reported 
(3). When cross-reactions were noted 
between several rickettsial antigens, 
Western blot (WB) assays and cross-
absorption studies were performed as 
previously described (4). A total of 
277 patients were included. We report 
2 confi rmed cases of R. typhi infection 
in patients from Algeria.
The fi rst patient, a 42-year-old 
male pharmacist who reported con-
tact with cats and dogs parasitized by 
ticks, consulted with our clinic for a 
10-day history of high fever, sweating, 
headache, arthralgia, myalgia, cough, 
and a 6-kg weight loss. He had not re-
ceived any antimicrobial drugs before 
admission. No rash, eschar, or specifi c 
signs were found. Standard laboratory 
fi ndings were within normal limits. No 
acute-phase serum sample was sent 
for testing. However, IFAs on conva-
lescent-phase serum were negative for 
SFG antigens (except R. felis: immu-
noglobulin [Ig] G 64, IgM 128), but 
they showed raised antibodies against 
R. typhi and R. prowazekii (IgG 2,048, 
IgM 1,024). 
The second patient, a 25-year-old 
farmer, was hospitalized for a 5-day 
history of fever, headache, diarrhea, 
and lack of response to treatment with 
amoxicillin and acetaminophen. He 
reported contact with cats and cattle. 
A discrete macular rash and pharyn-
gitis were observed. Standard labo-
ratory fi ndings were within normal 
limits, except neutrophil count was 
elevated at 11.2/μL (normal levels 
3–7/μL). Acute-phase serum was nega-
tive for rickettsial antigens. Convales-
cent-phase serum obtained 2 weeks 
later was positive for several SFG an-
tigens (IgM only; the highest level was 
256 for R. conorii), and higher levels 
of antibodies were obtained against R. 
typhi and R. prowazekii (IgG 256, IgM 
256). WB and cross-absorption studies 
confi rmed R. typhi infection (Figure). 
Both patients recovered after a 3-day 
oral doxycycline regimen and have re-
mained well. (A single 200-mg dose of 
oral doxycycline usually leads to defer-
vescence within 48–72 hours [1]).
Murine typhus is a mild disease 
with nonspecifi c signs. Less than half 
of patients report exposure to fl eas or 
fl ea hosts. Diagnosis may be missed 
because the rash, the hallmark for 
rickettsial diseases, is present in <50% 
of patients and is often transient or 
diffi cult to observe. Arthralgia, my-
algia, or respiratory and gastrointes-
tinal symptoms, as reported here, are 
frequent; neurologic signs may also 
occur (5). As a consequence, the clini-
cal picture can mimic other diseases. 
A review has reported 22 different 
diagnoses that were proposed for 80 
patients with murine typhus in the 
United States (6).
Serologic tests are the most fre-
quently used and widely available 
methods for diagnosis of rickettsioses 
(7). IFA is the reference method (7). 
However, R. typhi may cross-react 
with other rickettsial antigens, includ-
ing SFG rickettsiae, but especially 
with the other typhus group rickettsia, 
R. prowazekii, the agent of epidemic 
typhus (8). Epidemic typhus is trans-
mitted by body lice and occurs more 
frequently in cool areas, where clothes 
are infrequently changed, and particu-
larly during human confl icts. It is still 
prevalent in Algeria (9).
This cross-reactivity led to some 
diffi culties in interpreting serologic 
results (10). However, WB and cross-
adsorption studies can be used when 
cross-reactions occur between rickett-
sial antigens. They are useful for iden-
tifying the infecting rickettsia to the 
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Figure. Western blot assay and cross-adsorption studies of an immunofl uoresence assay–
positive serum sample from a patient with rickettsiosis in Algeria. Antibodies were detected 
at the highest titer (immunoglobulin [Ig] G 256, IgM 256) for both Rickettsia typhi and R. 
prowazekii antigens. Columns Rp and Rt, Western blots using R. prowazekii and R. typhi 
antigens, respectively. MW, molecular weight, indicated on the left. When adsorption is 
performed with R. typhi antigens (column Ads with Rt Ag), it results in the disappearance of 
the signal from homologous and heterologous antibodies, but when it is performed with R. 
prowazekii antigens (column Ads with Rp Ag), only homologous antibody signals disappear, 
indicating that the antibodies are specifi c for R. typhi.
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species level and for providing new 
data about the emergence or reemer-
gence of rickettsioses, as reported 
here. These assays are, however, time-
consuming and only available in spe-
cialized reference laboratories. 
Clinicians need to be aware of the 
presence murine typhus in Algeria, es-
pecially among patients with unspecif-
ic signs and fever of unknown origin. 
Tetracyclines remain the treatment of 
choice. 
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Natural Co-infec-
tion with 2 Parvovi-
rus Variants in Dog 
To the Editor: Canine parvovirus 
(CPV) emerged in the late 1970s, pre-
sumably by mutations in feline pan-
leukopenia virus, and became a major 
viral pathogen of dogs worldwide (1). 
Between 1979 and 1981, the original 
type 2 virus (CPV-2) was replaced by 
a new genetic and antigenic variant, 
type 2a (CPV-2a). Between 1983 and 
1984, CPV-2a was replaced by type 
2b (CPV-2b), which differs from type 
2a by only 1 epitope located at resi-
due 426 of the VP2 capsid protein (2). 
CPV-2 does not replicate in cats, but 
the new variants replicate in dogs and 
cats (3). Recently, an antigenic change 
has been observed in a new strain, 
CPV-2c, isolated from domestic dogs 
in Italy (4). This variant was also de-
tected in Vietnam (5), other countries 
in Europe (6), and the United States 
(7). CPV-2c was recently detected in 
cats (8) and is characterized by a re-
placement of aspartic acid with glu-
tamic acid at residue 426 of the VP2 
capsid protein.
To identify CPV types 2, 2a, and 
2b, PCR methods were developed (9). 
However, these methods could not 
distinguish type 2c from type 2b (4). 
Consequently, we used a PCR–restric-
tion fragment-length polymorphism 
(RFLP) assay with endonuclease 
MboII. This enzyme can distinguish 
type 2c from other CPVs (4). Re-
cently, a real-time PCR assay based 
on minor groove binder (MGB) probe 
technology was developed for rapid 
identifi cation and characterization of 
the antigenic variants. This assay is 
based on 1 nucleotide polymorphism 
in the VP2 gene (10).
In June 2006, a 10-week-old fe-
male dog (PT-32/07) was brought to 
the veterinary clinic in Figueira da 
Foz, Portugal, with clinical signs of 
parvovirus infection, after an episode 
of  gastrointestinal disease in her litter-
mates. Three littermates, also brought 
to the clinic, showed no signs of infec-
tion. None of the dogs were vaccinated 
against CPV. Clinical signs in dog PT-
32/07 were lethargy, anorexia, vom-
iting, diarrhea, and a temperature of 
39.3°C. Identical signs were observed 
in 1 littermate 3 days later; the 2 other 
dogs did not show any signs other than 
lethargy and loose stools. 
Rectal swab samples from all 
dogs were screened for CPV by using 
an immunomigration rapid test (Syn-
biotics Corporation, Lyon, France). 
Two of the dogs showed negative 
results, and 2 showed positive re-
sults. Feces, serum, and lingual swab 
samples were positive for parvovirus 
DNA. DNA was quantifi ed by using a 
real-time PCR with TaqMan technol-
ogy performed in an i-Cycler iQ (Bio-
Rad Laboratories, Milan, Italy).
CPV variants were characterized 
by using MGB probe technology. This 
technology uses type-specifi c probes 
labeled with different fl uorophores 
(FAM and VIC) that can detect single 
nucleotide polymorphisms between 
CPV types 2a/2b and 2b/2c (10). 
MGB probes specifi c for type 2b were 
labeled with FAM in both type 2a/2b 
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